Inhibitory Effect Of LSKL Peptide On Subarachnoid Fibrosis After SAH

Objective:to detect the small molecular peptide LSKL can pass the blood-brain barrier, and analyze the inhibitory effect of LSKL peptide on SAH after subarachnoid fibrosis in.Methods:rats by intravenous injection of LSKL peptide, detection of LSKL peptide concentration in blood and cerebrospinal fluid. Establishment of experimental rat model of subarachnoid hemorrhage (subarachoid web hemorrhage, SAH) model, the detection of LSKL peptide activation of TGF-beta on TSP-1SAH in cerebrospinal fluid after subarachnoid cavity effect and degree of fibrosis and ventricular enlargement degree of treatment prevention.Results:the LSKL peptide in5minutes in the cerebrospinal fluid of the highest, intravenous administration of LSKL peptide can inhibit the SAH induced by TGF-β1activation, high expression of TSP-1, reduce the activation of TGF-β1and the ratio of smad2. Compared with the SAH model group, LSKL treatment group also decreased the expression of type I collagen and α-SMA, hydrocephalus ratio is reduced from45%to10%.Conclusion:LSKL peptide can pass through the blood brain barrier, activation and inhibition of SAH in cerebrospinal fluid by TGF-β1and its downstream signaling pathway. Intravenous administration of LSKL peptides can cause effectively slow down SAH after subarachnoid fibrosis and ventricular enlargement...